BiotechTube
Radiance Therapeutics

Radiance Therapeutics

Cambridge, United States· Est.
radiancetherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $21.5M

Overview

Radiance Therapeutics is a private, early-stage medical device company focused on the ophthalmic surgery market, specifically for glaucoma. Founded in 2021 and headquartered in the biotech hub of Cambridge, Massachusetts, the company appears to be in a pre-revenue, pre-clinical or prototype development stage. The available information suggests a pivot or significant clarification in its business focus from a previously stated aim in radiopharmaceuticals to a concrete development program for a surgical device.

OphthalmologyGlaucoma

Technology Platform

Ophthalmic surgical device technology for glaucoma procedures; specific platform details undisclosed.

Funding History

2
Total raised:$21.5M
Series A$17.5M
Seed$4M

Opportunities

The global glaucoma surgical device market is large and growing, particularly the minimally invasive glaucoma surgery (MIGS) segment.
An innovative device that improves surgical outcomes, reduces complications, or simplifies procedures could capture significant market share or become an attractive acquisition target for a major ophthalmic company.

Risk Factors

The company is at an extremely early stage with a single, undisclosed asset, posing high technical and development risk.
A major discrepancy exists between provided data (cancer radiopharmaceuticals) and the website (ophthalmic device), creating strategic clarity concerns.
The competitive landscape in glaucoma devices is intense, with well-funded incumbents.

Competitive Landscape

Radiance would compete in the crowded and innovative glaucoma surgical device market, dominated by large medtech players like Alcon, Johnson & Johnson Vision, and Glaukos, as well as several smaller specialized firms. Success requires demonstrating clear differentiation in efficacy, safety, or cost over existing MIGS implants, stents, and surgical tools.

More companies in Drug Delivery & Formulation →More companies in United States →